Send us a link
European universities are behind more than 10% of all patent applications filed at the EPO from within Europe. However, wide variations in patterns of ownership and commercialisation are much in evidence.
Patents remain an important way for research-intensive universities to exploit their work, but the commercialisation scene is changing.
A patent waiver will not help guarantee COVID-19 vaccines equity around the world and instead richer countries should back compulsory licensing, says a new report by the European Federation of Academies of Sciences and Humanities (ALLEA).
Researchers and intellectual-property specialists offer their tips for deciding which discoveries are worth patenting, and how to do the homework needed for success.
Inventor teams with women represent 16% of filed patents, yet are more likely than male teams to create women's health products.
A preliminary network analysis highlights the complex intellectual property landscape behind mRNA-based COVID-19 vaccines.
With a poor return of value, and a huge overhead for research, patents are a bad investment for the academy, this article argues.
